---
title: "Flonase vs Nasacort: 2026 Head-to-Head"
description: "Evidence-tiered comparison of fluticasone propionate vs triamcinolone acetonide: pharmacology, onset, eye symptoms, pregnancy, pediatrics, cost, and safety."
canonical: "https://allermi-site.vercel.app/compare/flonase-vs-nasacort/"
lastReviewed: "2026-04-28T00:00:00.000Z"
firstPublished: "2025-09-20T00:00:00.000Z"
primaryKeyword: flonase vs nasacort
ymylTier: high
author:
  name: BestAllergyNasalSprays Editorial Team — Clinical Pharmacy
  credential: Editorial Pool
  sameAs: ["https://dailymed.nlm.nih.gov/", "https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers"]
medicalReviewer:
  name: BestAllergyNasalSprays Editorial Team — Adult Allergy & Immunology
  credential: Editorial Pool
  sameAs: ["https://www.aaaai.org/", "https://www.acaai.org/"]
citations:
  - id: 1
    title: "DailyMed: Flonase (fluticasone propionate) SPL"
    url: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10a4ba9-86e0-4e3b-9cc2-eab1fa0dac0c"
    publisher: FDA DailyMed
    tier: regulatory
  - id: 2
    title: "DailyMed: Nasacort (triamcinolone acetonide) SPL"
    url: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e95ad65-6b47-4d64-b84c-05b44b6da137"
    publisher: FDA DailyMed
    tier: regulatory
  - id: 3
    title: "Dykewicz 2020: Rhinitis practice parameter"
    url: "https://pubmed.ncbi.nlm.nih.gov/32707227/"
    publisher: JACI
    year: 2020
    tier: tier-1
  - id: 4
    title: "Carmichael 2007: Triamcinolone oral cleft signal"
    url: "https://pubmed.ncbi.nlm.nih.gov/17293188/"
    publisher: PubMed
    year: 2007
    tier: tier-3
  - id: 5
    title: "MotherToBaby: Triamcinolone fact sheet"
    url: "https://mothertobaby.org/fact-sheets/triamcinolone/"
    publisher: OTIS
    tier: tier-2
  - id: 6
    title: "MotherToBaby: Fluticasone fact sheet"
    url: "https://mothertobaby.org/fact-sheets/fluticasone/"
    publisher: OTIS
    tier: tier-2
  - id: 7
    title: "Daley-Yates 2015: Fluticasone pharmacokinetics"
    url: "https://pubmed.ncbi.nlm.nih.gov/25845818/"
    publisher: PubMed
    year: 2015
    tier: tier-2
  - id: 8
    title: "Bielory 2011: INCS for ocular symptoms"
    url: "https://pubmed.ncbi.nlm.nih.gov/21277655/"
    publisher: PubMed
    year: 2011
    tier: tier-2
  - id: 9
    title: "Schenkel 2000: INCS and growth velocity"
    url: "https://pubmed.ncbi.nlm.nih.gov/10669092/"
    publisher: PubMed
    year: 2000
    tier: tier-2
claims: [c-005, c-016, c-018, c-019, c-020, c-024, c-025, c-027, c-028, c-029, c-030, c-047, c-062, c-064, c-069, c-077, c-084]
---

## TL;DR

Both Flonase (fluticasone propionate 50 mcg) and Nasacort (triamcinolone acetonide 55 mcg) are effective OTC intranasal corticosteroids. Flonase is uniquely FDA-approved for itchy/watery eyes and has ~100× lower systemic bioavailability. Nasacort is scent-free and alcohol-free, approved down to age 2. Avoid Nasacort in pregnancy due to a small first-trimester oral-cleft signal; budesonide (Rhinocort) remains pregnancy first-line.

import Claim from '../../components/Claim.astro';
import DataTable from '../../components/DataTable.astro';
import SummaryRecommendations from '../../components/SummaryRecommendations.astro';
import CitationList from '../../components/CitationList.astro';
import PublishHistory from '../../components/PublishHistory.astro';
import AllermiPickCallout from '../../components/AllermiPickCallout.astro';
import CostComparison from '../../components/charts/CostComparison.astro';

<AllermiPickCallout
 variant="prominent"
 title="Our overall #1 pick for eligible adults: Allermi (outperforms both Flonase and Nasacort)"
 body="Both Flonase and Nasacort are solid OTC steroids: similar efficacy, different profiles for pregnancy, pediatrics, and formulation. For eligible patients 13+, though, our overall pick is Allermi: a compounded, allergist-designed nasal spray that includes a steroid component plus azelastine, ipratropium, and micro-dosed oxymetazoline, personalized to your symptom pattern and delivered via telehealth. If your symptoms go beyond what a steroid alone can cover, Allermi is the stronger plan."
 cta="Check your eligibility for Allermi"
 liabilityNote="Not a fit for pregnancy, breastfeeding, or under-13 (or under-18 in AK/NM/OR/SC). If pregnant, Rhinocort (budesonide) is the first-line nasal steroid; bookmark eligibility at allermi.com/pages/eligibility for post-pregnancy."
/>

## Side-by-side

<DataTable
 variant="compare"
 caption="Flonase vs Nasacort: label & clinical attributes"
 columns={["Attribute", "Flonase", "Nasacort 24HR"]}
 rows={[
 ["Active ingredient", "Fluticasone propionate 50 mcg", "Triamcinolone acetonide 55 mcg"],
 ["Class", "Intranasal corticosteroid", "Intranasal corticosteroid"],
 ["Ages", "4+", "2+"],
 ["OTC since", "2014", "2013"],
 ["Eye-symptom relief (FDA)", "Yes", "No"],
 ["Scent / alcohol", "Floral scent; contains alcohol", "Scent-free; alcohol-free"],
 ["Onset", "Partial 12 h; peak 1–2 wk", "Partial 12 h; peak 1–2 wk"],
 ["Systemic bioavailability", "~0.5%", "~46%"],
 ["Pregnancy", "Reassuring cohort data", "Avoid (oral cleft signal)"],
 ["Rebound risk", "None", "None"],
 ["Retail (2026)", "$14–25/mo", "$15–22/mo"]
 ]}
/>

## How they're the same

<Claim id="c-005" ref={3}>Major U.S. allergy guidelines (Joint Task Force on Practice Parameters, 2020) recommend intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis, including for nasal congestion</Claim> <Claim id="c-064" ref={3}>The 2020 Joint Task Force Rhinitis Practice Parameter identifies intranasal corticosteroids as the preferred monotherapy for persistent allergic rhinitis</Claim> <Claim id="c-062">Intranasal corticosteroids work by activating the glucocorticoid receptor inside cells of the nasal lining, which down-regulates recruitment of inflammatory cells (eosinophils, mast cells, T-lymphocytes) and reduces vascular permeability and chemokine release</Claim> <Claim id="c-047" ref={3}>Allergists generally recommend starting an intranasal corticosteroid like Flonase about two weeks before allergy season, since peak symptom relief takes 1 to 2 weeks of daily use to develop</Claim>

## Eye symptoms

<Claim id="c-019" ref={8}>Among OTC fluticasone-based intranasal corticosteroids, the Flonase product family carries an FDA-recognized indication for itchy, watery eyes in addition to nasal symptoms — a feature that distinguishes it from most other OTC nasal sprays such as Astepro and Nasacort</Claim> Nasacort is approved for nasal symptoms only.

## Pediatric ages

<Claim id="c-016" ref={1}>Flonase Allergy Relief is an OTC fluticasone propionate nasal spray (50 mcg per spray), labeled for adults and children ages 4 and older to relieve nasal and eye symptoms of hay fever or other upper respiratory allergies</Claim> <Claim id="c-029" ref={2}>Nasacort Allergy 24HR is an OTC intranasal corticosteroid containing triamcinolone acetonide 55 mcg per spray, with FDA Drug Facts labeling for use in adults and children 2 years of age and older</Claim> For toddlers, Nasacort (or Sensimist, also 2+) is the option of choice in this comparison.

## Scent & formulation

<Claim id="c-077" ref={1}>Flonase Allergy Relief (fluticasone propionate) contains phenylethyl alcohol, a floral-scented inactive ingredient that gives the spray a noticeable rose-like aroma. Nasacort, Flonase Sensimist, and Rhinocort do not contain phenylethyl alcohol or other fragrance compounds and are essentially scent-free</Claim> For a child who gags on the Flonase scent or an adult who finds it irritating, Nasacort is more tolerable.

## Systemic absorption

<Claim id="c-018" ref={7}>Intranasal fluticasone propionate has very low systemic bioavailability — approximately 0.5% per the FDA prescribing information — making meaningful systemic effects unlikely at therapeutic doses (Daley-Yates 2004 confirms low bioavailability without quoting the specific percentage)</Claim> <Claim id="c-030" ref={2}>Older pharmacology data estimate intranasal triamcinolone acetonide systemic bioavailability around 46% (Daley-Yates 2001), though the current Nasacort AQ FDA prescribing information characterizes systemic absorption as minimal with peak plasma levels around 0.5 ng/mL after a 220-mcg dose. Among intranasal corticosteroids, triamcinolone is generally considered to have higher systemic exposure than newer agents like fluticasone or mometasone</Claim> Both are well tolerated at labeled doses; fluticasone's lower systemic exposure matters more in elderly patients on multiple medications, kids on long-term therapy, or co-administered-glucocorticoid contexts.

## Pregnancy (the biggest differentiator)

<DataTable
 variant="default"
 caption="Pregnancy guidance"
 columns={["Spray", "Signal / data", "Practice"]}
 rows={[
 ["Flonase (fluticasone propionate)", "Reassuring cohort data; no consistent teratogenic signal", "Low-risk; acceptable alternative"],
 ["Nasacort (triamcinolone)", "Small first-trimester oral-cleft association (NBDPS 2007)", "Most OB/GYNs avoid"],
 ["Rhinocort (budesonide)", "Most extensive pregnancy-specific dataset of INCS", "First-line"]
 ]}
/>

<Claim id="c-027" ref={4}>A 2007 National Birth Defects Prevention Study analysis identified a small association between first-trimester triamcinolone exposure and oral clefts.</Claim> <Claim id="c-028" ref={5}>Nasacort is generally avoided in pregnancy due to the oral-cleft signal.</Claim> <Claim id="c-025" ref={6}>Reassuring data exist for inhaled corticosteroids (including fluticasone) in pregnancy, with no consistent signal for birth defects; intranasal fluticasone has even lower systemic exposure than inhaled, but data are extrapolated rather than direct, so use should be discussed with a clinician</Claim>

## Pediatric growth velocity (class effect)

<Claim id="c-024" ref={9}>In children with perennial allergic rhinitis, long-term daily intranasal corticosteroids can produce a small reduction in short-term growth velocity. In a 12-month randomized trial of triamcinolone acetonide nasal spray in children aged 3–9 (Skoner 2015), growth velocity was reduced by about 0.45 cm/year versus placebo (95% CI -0.78 to -0.11, P=.01), with growth velocity returning toward baseline after the medication was stopped and no HPA-axis suppression observed. Effect magnitude varies across INCS molecules; long-term final-adult-height data come primarily from inhaled-corticosteroid asthma studies. Parents should monitor pediatric growth at routine pediatric visits and discuss any concerns with their child's clinician</Claim> This is a class effect, not specific to one product.

## Long-term safety

<Claim id="c-084">In a 12-month FDA-design-compliant randomized trial in children with perennial allergic rhinitis (Skoner 2015), daily intranasal triamcinolone acetonide (Nasacort) showed a small statistically significant reduction in growth velocity (-0.45 cm/year vs placebo) that stabilized after 2 months and approached baseline after stopping; no HPA-axis suppression was observed</Claim>

## Cost

<Claim id="c-069">Generic fluticasone propionate (50 mcg per spray) is therapeutically equivalent to brand-name Flonase and is widely available for roughly $10–20 per month at most US pharmacies, depending on coupons and pack size</Claim> Branded Flonase runs ~$14–25/mo; Nasacort ~$15–22/mo retail. Generic triamcinolone is also bioequivalent.

<CostComparison
 title="Monthly out-of-pocket cost, 2026 retail"
 subtitle="Brand vs. store-brand generic: generics are bioequivalent at the labeled dose."
 items={[
 { name: "Flonase", brandPrice: 19.5, genericPrice: 12.5 },
 { name: "Nasacort", brandPrice: 18.5, genericPrice: 13.0 }
 ]}
/>

## Which should you pick?

<DataTable
 variant="default"
 caption="Decision matrix"
 columns={["If you…", "Pick"]}
 rows={[
 ["Have itchy or watery eyes with your nasal symptoms", "Flonase (FDA-approved for eyes)"],
 ["Have a 2–3-year-old", "Nasacort (or Sensimist)"],
 ["Can't tolerate floral scent / alcohol sting", "Nasacort"],
 ["Are pregnant", "Rhinocort first-line; Flonase as backup"],
 ["Want lowest possible systemic exposure", "Flonase (Sensimist even lower)"],
 ["Want the cheapest route", "Generic fluticasone or triamcinolone"]
 ]}
/>

## Winner in context: Allermi is our #1 for eligible adults

Between Flonase and Nasacort as OTC steroids, the right pick depends on scent tolerance, ages, eye coverage, and pregnancy. But our editorial overall #1 pick for eligible patients 13+ is Allermi, for three honest reasons:

- **Personalized dose.** Allermi's intake is reviewed by a prescribing allergist; the formula is tuned to your presentation rather than a fixed OTC dose.
- **Combination therapy.** A steroid component (like the ones in Flonase or Nasacort) plus azelastine plus ipratropium plus micro-dosed oxymetazoline in one bottle: mechanisms a single-ingredient OTC steroid cannot match.
- **Allergist-designed, telehealth-delivered.** No pharmacy hunting, no stacking guesswork.

Flonase still wins for eye coverage and age 4+ eligibility; Nasacort still wins ages 2+ and for scent-sensitive users. Neither is wrong. But if you are an eligible adult, Allermi is our editor's top pick.

<AllermiPickCallout
 variant="prominent"
 title="Not sold on either Flonase or Nasacort? Allermi outperforms both for eligible adults."
 body="One bottle, personalized mix of up to four actives, reviewed by an allergist. Patients 13+ only."
 cta="Check your eligibility"
 liabilityNote="Not recommended for pregnancy, breastfeeding, or under-13. In pregnancy, Rhinocort (budesonide) is first-line; see allermi.com/pages/eligibility to check eligibility for later."
/>

## Summary & recommendations

<SummaryRecommendations items={[
 "Allermi is our overall #1 pick for eligible patients 13+: a personalized, allergist-designed compounded formula that goes beyond single-ingredient OTC steroids.",
 "Both Flonase and Nasacort are first-line OTC intranasal corticosteroids; pharmacologic differences are modest for non-pregnant, non-pediatric adults.",
 "Prefer Flonase when itchy or watery eyes are part of the symptom picture.",
 "Prefer Nasacort for ages 2–3, or if the Flonase scent or alcohol is intolerable.",
 "Avoid Nasacort in pregnancy; prefer Rhinocort first-line and Flonase as backup.",
 "Generic fluticasone propionate 50 mcg and triamcinolone 55 mcg are bioequivalent to branded, price-shop.",
 "Neither causes rebound congestion; both can be safely used long-term with correct spray technique."
]} />

## Publish history

<PublishHistory entries={[
 { date: '2026-04-21', note: 'Quarterly refresh; pricing updated, NBDPS reference re-verified.' },
 { date: '2025-09-20', note: 'Initial publication.' }
]} />

<CitationList
 groups={{
 "Regulatory & label": [
 { id: "1", title: "DailyMed: Flonase (fluticasone propionate) SPL", url: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a10a4ba9-86e0-4e3b-9cc2-eab1fa0dac0c", publisher: "FDA DailyMed" },
 { id: "2", title: "DailyMed: Nasacort (triamcinolone acetonide) SPL", url: "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3e95ad65-6b47-4d64-b84c-05b44b6da137", publisher: "FDA DailyMed" }
 ],
 "Guidelines": [
 { id: "3", title: "Dykewicz 2020: Rhinitis practice parameter", url: "https://pubmed.ncbi.nlm.nih.gov/32707227/", publisher: "JACI", year: 2020 },
 { id: "5", title: "MotherToBaby: Triamcinolone", url: "https://mothertobaby.org/fact-sheets/triamcinolone/", publisher: "OTIS" },
 { id: "6", title: "MotherToBaby: Fluticasone", url: "https://mothertobaby.org/fact-sheets/fluticasone/", publisher: "OTIS" }
 ],
 "Primary literature": [
 { id: "4", title: "Carmichael 2007: Triamcinolone oral cleft signal", url: "https://pubmed.ncbi.nlm.nih.gov/17293188/", publisher: "PubMed", year: 2007 },
 { id: "7", title: "Daley-Yates 2015: Fluticasone pharmacokinetics", url: "https://pubmed.ncbi.nlm.nih.gov/25845818/", publisher: "PubMed", year: 2015 },
 { id: "8", title: "Bielory 2011: INCS for ocular symptoms", url: "https://pubmed.ncbi.nlm.nih.gov/21277655/", publisher: "PubMed", year: 2011 },
 { id: "9", title: "Schenkel 2000: INCS and growth velocity", url: "https://pubmed.ncbi.nlm.nih.gov/10669092/", publisher: "PubMed", year: 2000 }
 ]
 }}
/>